Appili Therapeutics Announces Second Amendment to Arrangement Agreement

Core Viewpoint - Appili Therapeutics Inc. has entered into a second amending agreement with Aditxt, Inc. and Adivir, Inc. to modify the previously announced arrangement agreement for Aditxt to acquire all issued and outstanding Class A common shares of Appili through a court-approved plan of arrangement [1] Group 1: Transaction Details - The Outside Date for the transaction has been extended from August 30, 2024, to September 30, 2024 [2] - The deadline to convene the Company's special shareholders' meeting has also been changed to September 30, 2024 [2] - The deadline for Aditxt to complete the Financing has been modified from August 30, 2024, to September 15, 2024, or a later date as agreed by the Parties [2] Group 2: Company Overview - Appili Therapeutics is focused on drug development for infectious diseases and medical countermeasures, aiming to address urgent infections with unmet needs [4] - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate against biological weapon threats, and a topical antiparasitic treatment [4] - Appili is led by a proven management team and is positioned at the forefront of the global fight against infections [4]